DBV Technologies (DBVT) Tax Provisions (2020 - 2026)
DBV Technologies (DBVT) posted Tax Provisions of $200000.0 for Q2 2026, little changed sequentially from $200000.0 in Q1 2026, and up 100.0% YoY from $100000.0 in Q2 2025.
Analysis
DBV Technologies (DBVT) Tax Provisions (2020 - 2026) Analysis & Trends
DBV Technologies has reported Tax Provisions for 7 years, with the latest figure at $200000.0 in Q2 2026.
- Quarterly Tax Provisions rose 100.0% year-over-year to $200000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $774000.0 (up 623.36% YoY) and the FY2025 annual result came in at $491000.0, up 792.73% from the prior year.
- Tax Provisions held at $200000.0 in Q2 2026 per DBVT's latest filing, from $200000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $374000.0 in Q4 2025 and troughed at -$17000.0 in Q4 2022.
- A 5-year average of $100600.0 and a median of $67500.0 in 2022 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2022 and 2025: Tax Provisions slumped 173.91% in 2022, then surged 5242.86% in 2025.
- Over 5 years, Tax Provisions stood at -$17000.0 in 2022, then surged by 64.71% to -$6000.0 in 2023, then soared by 216.67% to $7000.0 in 2024, then soared by 5242.86% to $374000.0 in 2025, then slumped by 46.52% to $200000.0 in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered $200000.0, $200000.0, and $374000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 1.90 Mn |
| 10 | DBV Technologies | 5.87 Bn | 5.70 Bn | - | 200,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 200,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 374,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Mar 31, 2024 | 48,000.00 |
| Dec 31, 2023 | -6,000.00 |
| Jun 30, 2023 | 13,000.00 |
| Dec 31, 2022 | -17,000.00 |
| Mar 31, 2022 | 87,000.00 |
| Dec 31, 2021 | 23,000.00 |
| Jun 30, 2021 | -434,000.00 |
| Mar 31, 2021 | 30,000.00 |
| Dec 31, 2020 | -20,000.00 |
| Sep 30, 2020 | 7,000.00 |
| Jun 30, 2020 | 3,000.00 |